Back to results
US 2026/0028343 A1Published application
Substituted Imidazopyrazine Compounds as Ligand Directed Degraders of IRAK3
AssigneeCelgene Corporation
InventorsFarid van der Mei, Guobin Miao, Rulin Ma, Laura Akullian D'Agostino, Kurt Armbrust
Life of this patent
Estimating the term…
Abstract
Provided herein are compounds and compositions thereof for modulating IRAK3. In some embodiments, the compounds and compositions are provided for treatment of cancer.
Claims20
A compound of Formula (I):
- or a pharmaceutically acceptable salt thereof, wherein:
- Ring A is C6-C10 aryl or 5- to 6-membered heteroaryl, wherein the heteroaryl contains 1-3 heteroatoms selected from nitrogen, oxygen, and sulfur;
- Ring B is C6-C10 aryl or C3-C6 cycloalkyl, each of which is optionally substituted by 1-5 substituents selected from C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, halo, —OH, and —CN;
- X is CH or N;
- L is —O(C1-C6 alkylene)C(O)—, —O(C1-C6 alkylene)C(O)NR1(C1-C6 alkylene)C(O)—, —O(C1-C6 alkylene)C(O)NR1(C1-C6 alkylene)-O—(C1-C6 alkylene)C(O)—, —O(C1-C6 alkylene)C(O)NR1(C1-C6 alkylene)-, or —C(O)(6- to 11-membered spiro heterocyclene)-;
- R1 is H or C1-C6 alkyl;
- and
- R2a and R2b are each H or are taken together to form an oxo group.
5 more elements
A compound selected from the compounds of Table 1 or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.